Hypertriglyceridemia as a cardiovascular risk factor. The end of a controversy?;Hipertrigliceridemia como factor de riesgo cardiovascular. ¿Fin de la controversia?

Medicina Clinica

Volumn 120, Issue 8, 2003, Pages 303-307

  Rubiés Prat, Juan ^a   Pedro Botet, Juan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037426113     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13043906     Document Type: Review

References (46)

1. NIH Consensus Development on triglyceride, high-density lipoprotein and coronary heart disease. JAMA 1993;269:505-10.
2. Rubins HB. The trouble with triglycerides. Arch Intern Med 2000;160:1903-4.
3. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000;86:943-9.
4. Albrink MJ, Man EB. Serum triglycerides in coronary artery disease. Arch Intern Med 1959;103:4-8.
5. Schaefer EJ. Familial lipoprotein disorders and premature coronary artery disease. Med Clin North Am 1994;78:21-39.
6. Brewer HB Jr, Santamarina-Fojo SM, Hoeg JM. Genetic dyslipoproteinemias. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven, 1996; p. 69-88.
7. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med 1998;338:1650-6.
8. Austin MA, Hokanson JE. Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease. Med Clin North Am 1994;78:99-115.
9. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70:3H-9H.
10. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-36.
11. Criqui MC, Heiss G, Cohn R, Cowan LD, Suchinadran CM, Bangdiwala S, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993;328:1220-5.
12. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-8.
13. Austin MA, McKnight B, Edwards KL, Bradley CM, MoNeely MJ, Psaty BM, et al. Cardiovascular disease mortality in familial forms of hypertrigliceridemia: a 20-year prospective study. Circulation 2000;101:2777-82.
14. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-7.
15. Assmann G, Schulte H, Von Eckardestein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77:1179-84.
16. Avins AL, Neunaus JM. Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med 2000;160:1937-44.
17. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
18. Shimo-Nakanishi Y, Urabe T, Hattori N, Watanabe Y, Nagao T, Yokochi M, et al. Polymorphism of the lipoprotein lipase gene and risk of atherothrombotic cerebral infarction in the Japanese. Stroke 2001;32:1481-6.
19. Hokanson JE. Functional variants in the lipoprotein lipase gene and risk of cardiovascular disease. Curr Opin Lipidol 1999;10:393-9 (erratum 2000;11:99).
20. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999;99:2901-7.
21. Julve J, Cirera S, Reina M, Batlle X, Martín Campos JM, González Sastre F, et al. Diagnóstico de la hiperquilomicronemia familiar debido a deficiencia de lipoproteinlipasa: estudio clínico, bioquímico y genético de un caso y análisis de las mutaciones identificadas en otros 10 casos. Clin Invest Arterioscler 2000;12:191-8.
22. Talmud PJ, Humphries SE. Genetic polymorphisms, lipoproteins and coronary artery disease risk. Curr Opin Lipidol 2001;12:405-9.
23. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001;12:297-304.
24. Waterworth DM, Ribalta J, Nicaud V, Dallongeville J, Humphries SE, Talmud P. Apo CIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation 1999;99:1872-7.
25. Brunzell JD, Deeb SS. Familial lipoproteinlipase deficiency, apo C-II deficiency, and lipase hepatic deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill Medical Publishing Division, 2001: p. 2789-816.
26. Dugi KA, Brandauer K, Schmidt N, Nau B, Schneider JG, Mentz S, et al. Low hepatic lipase activity is a novel risk factor for coronary artery disease. Circulation 2001;104:3057-62.
27. Hokanson JE, Cheng S, Snell-Bergeon JK, Fijol BA, Grow MA, Hung C, et al. A common promoter polymorphism in the hepatic lipase gene (LIPC-480C>T) is associated with an increased in coronary calcification in type 1 diabetes. Diabetes 2002;51:1208-13.
28. Thuren T. Hepatic lipase and HDL metabolism. Curr Opin Lipidol 2000;11:277-83.
29. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 1993;13:147-53.
30. Busch SJ, Barnhart RL, Martin GA, Fitzgerald MC, Yates MT, Mao SJ, et al. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem 1994;269:16376-82.
31. Mannninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45.
32. Robins SJ, Collins D, Wittes JT, Papademetrion V, Deedwania PC, Schaefer EJ, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91.
33. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21-7.
34. Lloyd-Jones DM, O'Donnell CJ, D'Agostino RB, Massaro J, Silbershats H, Wilson PWF. Applicability of cholesterol-lowering primary prevention trials to a general population. The Framingham Heart Study. Arch Intern Med 2001;161:949-54.
35. Austin MA. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol 1999;83:13F-6F.
36. Kane JP, Havel RJ. Disorders of biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill Medical Publishing Division, 2001: p. 2717-52.
37. Grundy SM. Small LDL, atherogenic dyslipidemia, and metabolic syndrome. Circulation 1997;95:1-4.
38. Packard CJ. Understanding coronary heart disease as a consequence of defective regulation of apolipoprotein B metabolism. Curr Opin Lipidol 1999;10:237-44.
39. Sniderman AD, Ribalta J, Castro Cabezas M. How should FCHL be defined and how should we think about its metabolic bases? Nutr Metab Cardiovasc Dis 2001;11:259-73.
40. Sniderman AD, Castro Cabezas M, Ribalta J, Carmena R, De Bruin TWA, De Graaf J, et al. A proposal to redefine familial combined hyperlipidaemia- Third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the Scientific Sessions of the European Society for Clinical Investigation. Eur J Clin Invest 2002;32:71-3.
41. Hodis HN. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation 1999;99:2852-4.
42. Malhey RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill Medical Publishing Division, 2001; p. 2835-62.
43. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
44. National Cholesterol Education Program. Adult Treatment Panel III Report. Disponible en: www.nhlbi.nih.gov
45. Grundy SM. United States cholesterol guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. Am J Cardiol 2001;88:23J-7J.
46. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2002;25(Suppl 1):74-7.